Mitsubishi UFJ Asset Management
RXRX icon

Mitsubishi UFJ Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Buy
57,437
+16,389
+40% +$54.6K ﹤0.01% 1015
2026
Q1 		$126K Sell
41,048
-1,014
-2% -$3.92K ﹤0.01% 1031
2025
Q4 		$177K Buy
42,062
+4,134
+11% +$20.5K ﹤0.01% 1036
2025
Q3 		$185K Buy
37,928
+75
+0.2% +$394 ﹤0.01% 998
2025
Q2 		$192K Buy
37,853
+6,989
+23% +$34.3K ﹤0.01% 981
2025
Q1 		$163K Buy
30,864
+2,587
+9% +$18.9K ﹤0.01% 977
2024
Q4 		$221K Buy
28,277
+7,902
+39% +$53.1K ﹤0.01% 976
2024
Q3 		$134K Sell
20,375
-1,917
-9% -$13.7K ﹤0.01% 1002
2024
Q2 		$167K Sell
22,292
-2,622
-11% -$22.9K ﹤0.01% 981
2024
Q1 		$248K Sell
24,914
-1,141
-4% -$12.7K ﹤0.01% 937
2023
Q4 		$252K Sell
26,055
-6,947
-21% -$49.5K ﹤0.01% 987
2023
Q3 		$252K Buy
33,002
+1,938
+6% +$19.3K ﹤0.01% 1001
2023
Q2 		$232K Buy
31,064
+10,285
+49% +$72K ﹤0.01% 1022
2023
Q1 		$139K Buy
20,779
+2,046
+11% +$16.2K ﹤0.01% 1065
2022
Q4 		$141K Buy
+18,733
New +$184K ﹤0.01% 1058
2022
Q2 		– Sell
-16,347
Closed -$117K – 1194
2022
Q1 		$117K Buy
16,347
+1,390
+9% +$14.8K ﹤0.01% 1116
2021
Q4 		$270K Buy
+14,957
New +$281K ﹤0.01% 1033

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mitsubishi UFJ Asset Management's RXRX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 40% in Q2 2026, buying an estimated $54.6K and bringing the position to 57,437 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Mitsubishi UFJ Asset Management first reported a position in RXRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $270K in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 57,437 shares of Recursion Pharmaceuticals worth $211K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 16,389 Recursion Pharmaceuticals shares in Q2 2026, an estimated $54.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1015 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • Mitsubishi UFJ Asset Management's Recursion Pharmaceuticals position peaked at $270K in Q4 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.